SeekIn is prepared to launch its LeukoPrint Molecular Karyotyping Test in European markets following receipt of CE Mark approval.

The new kit, intended for the diagnosis of leukaemias, has been designed to identify the copy number aberration (CNA) patterns in leukaemia patients depending on shallow whole-genome sequencing (sWGS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It can also assist haematologists in diagnosing and prognostic stratifying according to the European Leukemia Net (ELN), Revised International Prognostic Scoring System (IPSS-R) or Revised International Staging System (R-ISS) guidelines.

Leukaemias are a set of malignant blood and bone marrow disorders that can occur at any age.

Additionally, LeukoPrint is suitable for many other forms of haematological malignancies, such as multiple myeloma.

See Also:

SeekIn founder and CEO Mao Mao said: “With the advent of new DNA sequencing technologies, next-generation sequencing (NGS) based genetic testing has been implemented as a routine protocol for cancer diagnosis, risk stratification and treatment response evaluation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“LeukoPrint provides a cost-effective and simplified method for prompt and accurate CNA profiling in leukaemia patients. It utilised a standardised protocol, which can be readily extended to clinical laboratories worldwide.

“With the advantage of detecting CNAs of short DNA fragments, by incorporating with the routine diagnostic methods, LeukoPrint can benefit the conventional cytogenetics by improving diagnostic yield.”

The company further plans to receive regulatory approvals in other territories, such as China.

It claims that the new test provides high accuracy as well as sensitivity and that it can help patients avoid pain from needing to give multiple bone marrow samples.

LeukoPrint also makes molecular subtyping, prognostic stratification and treatment response monitoring accurate and comprehensive.